This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers visit http://www.djreprints.com.
Updated June 27, 2022 11:12 am ET / Original June 27, 2022 10:28 am ET
- Order Reprints
- Print Article
Shares of Axsome Therapeutics were soaring Monday after the biopharmaceutical company announced some good news in an attempt to gain Food and Drug Administration approval of AXS-05, its drug for major depressive disorder.
In a filing with the Securities and Exchange Commission, Axsome (ticker: AXSM) said it had received proposed labeling from the FDA last Friday related to its new drug application for AXS-05.